CA3142149A1 - Actrii-binding proteins and uses thereof - Google Patents

Actrii-binding proteins and uses thereof Download PDF

Info

Publication number
CA3142149A1
CA3142149A1 CA3142149A CA3142149A CA3142149A1 CA 3142149 A1 CA3142149 A1 CA 3142149A1 CA 3142149 A CA3142149 A CA 3142149A CA 3142149 A CA3142149 A CA 3142149A CA 3142149 A1 CA3142149 A1 CA 3142149A1
Authority
CA
Canada
Prior art keywords
seq
amino acid
acid sequence
actrii
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3142149A
Other languages
English (en)
French (fr)
Inventor
Ravindra Kumar
Jonathan Belk
Asya Grinberg
Dianne Sako
Roselyne CASTONGUAY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acceleron Pharma Inc
Original Assignee
Acceleron Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acceleron Pharma Inc filed Critical Acceleron Pharma Inc
Publication of CA3142149A1 publication Critical patent/CA3142149A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3142149A 2019-05-30 2020-05-29 Actrii-binding proteins and uses thereof Pending CA3142149A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962854625P 2019-05-30 2019-05-30
US62/854,625 2019-05-30
PCT/US2020/035148 WO2020243448A1 (en) 2019-05-30 2020-05-29 Actrii-binding proteins and uses thereof

Publications (1)

Publication Number Publication Date
CA3142149A1 true CA3142149A1 (en) 2020-12-03

Family

ID=73553540

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3142149A Pending CA3142149A1 (en) 2019-05-30 2020-05-29 Actrii-binding proteins and uses thereof

Country Status (8)

Country Link
US (1) US20220242956A1 (enExample)
EP (1) EP3976630A4 (enExample)
JP (2) JP7669291B2 (enExample)
KR (1) KR20220029563A (enExample)
CN (1) CN114127087A (enExample)
AU (1) AU2020284038A1 (enExample)
CA (1) CA3142149A1 (enExample)
WO (1) WO2020243448A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3211515A1 (en) * 2021-03-10 2022-09-15 Acceleron Pharma Inc. Actrii-alk4 antagonists and methods of treating heart failure
BR112023018283A2 (pt) * 2021-03-10 2023-10-31 Acceleron Pharma Inc Antagonistas de actrii-alk4 e métodos para tratar insuficiência cardíaca
CA3228901A1 (en) * 2021-09-03 2023-03-09 Chris Xiangyang Lu Anti-acvr2a antibodies and uses thereof
WO2025027052A1 (en) 2023-07-31 2025-02-06 Sixpeaks Bio Ag Antibody conjugates and fusion proteins
TW202513591A (zh) * 2023-08-01 2025-04-01 大陸商來凱醫藥科技（上海）有限公司 抗acvr2b抗體及其用途
AR133979A1 (es) * 2023-09-28 2025-11-19 Sixpeaks Bio Ag ANTICUERPOS DIRIGIDOS A ActRIIA Y ActRIIB

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2007002567A1 (es) * 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
EP3275900A1 (en) * 2009-04-27 2018-01-31 Novartis AG Compositions and methods for increasing muscle growth
US8765385B2 (en) * 2011-10-27 2014-07-01 Ravindra Kumar Method of detection of neutralizing anti-actriib antibodies
GR1007832B (el) * 2011-11-21 2013-02-14 Ιδρυμα Ιατροβιολογικων Ερευνων Ακαδημιας Αθηνων, Αδρανοποιητες της ακτιβινης και χρηση τους για την θεραπεια ασθενειων που σχετιζονται με παρεκκλινουσα ενεργοποιηση της "αμυντικης αποκρισης του ξενιστη"
MA37761A1 (fr) * 2012-06-11 2017-09-29 Amgen Inc Protéines de liaison à un antigène antagoniste d'un double récepteur et leurs utilisations
WO2014172448A2 (en) * 2013-04-17 2014-10-23 Anaptysbio, Inc. Antibodies directed against activin receptor type ii (actrii)
TW201920262A (zh) * 2013-07-30 2019-06-01 美商再生元醫藥公司 抗活化素ａ之抗體及其用途
RS61881B1 (sr) * 2015-04-22 2021-06-30 Biogen Ma Inc Novi hibridni actriib proteini zamke za ligand za lečenje bolesti gubljenja mišića
EP3420002A4 (en) 2016-02-22 2020-01-15 Acceleron Pharma Inc. ACTRII ANTAGONISTS FOR USE TO INCREASE IMMUNITY
EP3426680B1 (en) * 2016-03-10 2024-08-14 Acceleron Pharma Inc. Activin type 2 receptor binding proteins and uses thereof
PT3600415T (pt) * 2017-03-24 2025-11-24 Novartis Ag Anticorpo contra recetor de activina do recetor do tipo ii para utilização no tratamento de insuficiência cardíaca

Also Published As

Publication number Publication date
JP7669291B2 (ja) 2025-04-28
CN114127087A (zh) 2022-03-01
JP2022534966A (ja) 2022-08-04
WO2020243448A1 (en) 2020-12-03
EP3976630A1 (en) 2022-04-06
US20220242956A1 (en) 2022-08-04
KR20220029563A (ko) 2022-03-08
JP2025118664A (ja) 2025-08-13
WO2020243448A8 (en) 2022-05-05
EP3976630A4 (en) 2024-03-20
AU2020284038A1 (en) 2021-12-02

Similar Documents

Publication Publication Date Title
US20240374671A1 (en) Activin Type 2 Receptor Binding Proteins and Methods of Making Them
JP7669291B2 (ja) Ａｃｔｒｉｉ結合性タンパク質及びその使用
US20230416379A1 (en) ALK7 Binding Proteins and Uses Thereof
US12365736B2 (en) ALK7 binding proteins and uses thereof
WO2018035119A9 (en) Methods of treating cancer using bifunctional molecules that target growth factors
HK40003457A (en) Activin type 2 receptor binding proteins and uses thereof
HK40003457B (en) Activin type 2 receptor binding proteins and uses thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240510